Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression
    Meeting Abstract

    Klohe, E.; Suchindran, S.; Kapoor, G.; D'Souza, J.; Corigleano, E.; Araujo, D.; D'Angelo, S.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Saxena, U.; Bhaskar, A.; Kaczynski, H.; Nathenson, M.; D'Souza, J.; Rich, B.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
    Meeting Abstract

    Sanborn, R.; Gabrail, N.; Carneiro, B.; O'Hara, M.; Bordoni, R.; Gordon, M.; Khalil, D.; Hauke, R.; Taglienti, C.; Rogalski, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) ± tremelimumab (T) + platinumetoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN
    Meeting Abstract

    Xie, M.; Chugh, P.; O'Brien, C.; Lai, Z.; Stewart, R.; Paz-Ares, L.; Goldman, J.; Garassino, M.; Rudin, C.; Barrett, J. C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: Part 1 results
    Meeting Abstract

    Friedman, C.; Carvajal, R.; Davar, D.; Castanon, E.; Ascierto, P.; Calvo, E.; O'Hara, M.; Powell, S.; Shapira-Frommer, R.; Garralda, E.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Immunogenicity of durvalumab: Analysis of pooled pan-tumor data
    Meeting Abstract

    El-Khoueiry, A.; Zhou, D.; Ozguroglu, M.; Johnson, M.; Abou-Alfa, G.; Makowsky, M.; Krug, L.; Gupta, A.; Chen, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Amadeus trial: Tumor agnostic pre- and ontreatment biomarkers of response to nivolumab plus ipilimumab correlate with ontreatment tumoral T cell infiltration
    Meeting Abstract

    Alayli, F.; Okrah, K.; Tsimberidou, A.; Drakaki, A.; Khalil, D.; Khan, S.; Hodi, S.; Oh, D.; Amouzgar, M.; Guatam, S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214
    Meeting Abstract

    Gupta, S.; Han, C.; Dwivedi, B.; Li, J.; Karsdal, M.; Motzer, R.; Willumsen, N.; McDermott, D.; Choueiri, T.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 porter platform trial in metastatic castration-resistant prostate cancer patients
    Meeting Abstract

    Shotts, K.; Howes, T.; Yu, J.; Densmore, J.; Da Silva, D.; Kumar, D.; Santulli-Marotto, S.; Cabanski, C.; Eisenbeisz, E.; Ivison, G.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial
    Meeting Abstract

    Saatcioglu, H. D.; Valle, J.; Macarulla, T.; Javle, M.; Oh, D. Y.; Goyal, L.; Conway, J.; Iyer, J.; Najdawi, F.; Shah, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save